Could we be seeing the end of routine doctor visits?
Scientific American reports that researchers are testing a new system for electronic doctor visits that could potentially eliminate the need for patients to see a doctor for routine illnesses.
Patients would simply enter their symptoms and health record into an online system, and doctors would use this information to send a diagnosis and, when necessary, a prescription.
Early reports suggest that such diagnoses were just as accurate as those given in person, although there are still some kinks that need to be ironed out:
Researchers analyzed some 5,000 doctor visits for sinus infections and 3,000 visits for urinary tract infection. Less than 10 percent of all visits were electronic. One possible e-visit drawback: doctors were more likely to prescribe antibiotics after an e-visit than a face-to-face.
But patients with an e-visit had just about the same rate of follow up as those who had an office visit. Which suggests that there was not a higher rate of misdiagnosis or treatment failure online. E-visits were also cheaper.
Detractors will note that this program only applies to relatively routine illnesses, but even so, this is nothing to sneeze at.
One of the primary goals of Obamacare was to cut down on the use of expensive emergency room visits for routine medical care, which was clogging up emergency rooms and leading to millions of dollars in unpaid medical bills. This looks like a much cheaper and simpler way to accomplish the same thing.
Naturally, we’ll need to see more studies before these programs can be rolled out on a national scale, but this looks like a good place to start toward improving the ! efficien cy of the health care system. Massive, top-down reforms like Obamacare get most of the attention, but it is smaller innovations like these will do the most to shape the healthcare of the future.
It also seems clear that letting consumers benefit from cheaper prices is a way to push the health care system as a whole toward less costly methods. E-visits for routine problems (and ultimately, perhaps, e-visits to nurses rather than to physicians) can offer better, faster, more convenient service at a lower price. Moving in directions like this is the kind of health care reform we desperately need.
Amazon has nothing to worry about. Oracle will never win the cloud without developers.
No matter what Larry Ellison says on stage at Oracle Open World, Oracle will never match Amazon Web Services’ (AWS) first-class treatment of the developer community. Nor will Oracle even try: it’s a vertical iron machine that Ellison believes has the power to be the new “cloud” for IT. It is not a horizontal distributed, self-service environment that you get when you use AWS.
A couple weeks ago, Cipla pharmaceuticals ticked off the larger pharmaceutical firms when it announced it would begin offering its cancer treatment at a price 75% lower than its competitors. Specifically for kidney, lung, and brain cancer, the treatment is basically a copy, or generic, of Nexavar, co-developed and co-marketed by Bayer and Onyx Pharmaceuticals.
If Big Pharma thought that was bad, now they have to cope with the Indian government’s new plan to give away $5.4 billion in prescription drugs over the next 5 years, according to Reuters. And the news just kept getting worse, as India announced that branded drugs would be banned from the plan.
The policy, only operating in state-run hospitals and clinics, will allow public doctors to prescribe free generic medicines to ailing Indians. If doctors are caught prescribing branded drugs, disciplinary action will result.
With 40% of the population under the poverty line (living off of $1.25 or less), the average citizen spends just $4.50 in medial costs per year. Health care is seen as a luxury for the well-off, private clinics accounting for four times more health spending than public hospitals. Indian officials hope this plan helps change that, predicting that by the end of 2017, at least 52% of India’s 1.2 billion citizens will take advantage of the policy, according to the same Reuters article.
While figures for Big Pharma companies like Bayer and GlaxoSmithKline will surely be hit, Indian generic makers including Cipla will be set to benefit the most.
Companies like Google, Amazon, and Apple are currently competing for a new round of top-level domains—think new versions of
.app. They think this will make the internet easier to use, but we think it’s a bit sketchier than they’d like to admit. Here’s why.
What Is a Top-Level Domain?
A top-level domain is the last part of a URL, often something like
.org. It’s at the top of the domain hierarchy (hence the term “top-level”), and is the first thing your computer looks for when you type in a web address. When you type in
lifehacker.com, for example, your browser asks your DNS server where it can find the
.com nameserver. Your browser then contacts the
.com nameserver for the
lifehacker subdomain, where it finds this web site. You can see an example of this below, courtesy of Wikipedia.
These domain names are all managed by the Internet Corporation for Assigned Names and Numbers (ICANN), formerly a government organization but now a private, non-profit entity. ICANN not only manages which top-level domains exist, but also make sure everything is stable and runs smoothly.
ICANN Is Handing Out New Top-Level Domains, Lottery-Style
A few years ago, ICANN began expanding the number of top-level domains, so porn sites, for example, could use the
.xxx domain. Recently, though, they opened this up so companies can create and apply for custom top-level domains. For example, Google wants to claim
.blog, so all blogs created by their Blogger service would have an easy-to-remember
.blog domain name. They also want
.search for obvious reasons, while Amazon wants to claim
.cloud. Allowed domains can range from brands (like
.gmail) to generic words (
.fun) and geographic locations (
.paris). Not all top-level domains will be exclusive, but when a company applies for one, they can choose to make them exclusive to their own pages, like Google wants to do with
.blog. Many of these companies have applied for hundreds of top-level domains (ready to pay millions of dollars for them), even ending up in battles over who gets what—both Google and Amazon are currently fighting over
.cloud, for example, and you can bet everyone’s looking to get their hands on
Why the Domain Lottery Is Sketchy
As you can imagine, some people think this lottery is a little ridiculous, and we tend to agree. It might seem innocent enough to give Amazon ownership of the
.kindle domain, since the Kindle is their product, but you can easily see how things get more complex when they’re asking for an exclusive claim to the
.book domain, or Google the
.search domain. Not only that, but it opens the door for a lot of unfair treatment. It wouldn’t be out of character for Google to float
.blog sites to the top of search results, or the company who owns the
.news domain could give preferential treatment to sites that share its political biases. It ends up being a huge, confusing, and sometimes misleading mess—and the only ones who benefit are the companies and ICANN, who despite being a nonprofit, stands to make a ton of money from this endeavor. Photo by MoneyBlogNewz.
These controversial domain applications are still in review, but ICANN has yet to say or do anything that would lead us to believe they won’t accept them. All we can do now is wait and see. What do you think about the new generic top-level domains? Will they make the internet easier to use, or are they only going to benefit companies and confuse users? Share your thoughts with us in the comments below. And, if you’re interested in reading more, here are some other articles on the subject:
- Generic Top-Level Domain [Wikipedia]
- .blog, .lol, .foo: Google, Amazon Top List of Global TLD Applications [Ars Technica]
- Amazon’s Domain Power Play: We Want to Control Them All [CNET]
- New Internet Domain Names May Make for a More Tangled Web [Washington Post]
- Should Gooogle and Amazon Be Allowed to Control Domains? [GigaOM]
Dr. Augustine Fou is Digital Consigliere to marketing executives, advising them on digital strategy and Unified Marketing(tm). Dr Fou has over 17 years of in-the-trenches, hands-on experience, which enables him to provide objective, in-depth assessments of their current marketing programs and recommendations for improving business impact and ROI using digital insights.
Collaborators – Digital Profs
- Netflix vs Blockbuster - Perfect example of an industry replaced by a more efficient version of itself
- ActiveHours Gives You Your Paycheck Early, Free of Charge
- Try On New Glasses in Warby Parker's Virtual Booth
- The JKWeddingDance video was real; the viral effect was MANUFACTURED - Post 1 of 2
- Coke vs Pepsi vs Dr Pepper
- Marketing Costs Normalized to CPM Basis for Comparison
- Samsung 52 inch HDTV $9.99 at BestBuy - purchase receipt below (6:21a eastern time August 12, 2009)
- Smartphone Users Recall
- Facebook advertising metrics and benchmarks
- February 2016 (2)
- January 2016 (6)
- October 2015 (2)
- September 2015 (7)
- August 2015 (6)
- July 2015 (2)
- June 2015 (5)
- May 2015 (4)
- April 2015 (32)
- March 2015 (57)
- February 2015 (79)
- January 2015 (86)
- December 2014 (69)
- November 2014 (98)
- October 2014 (150)
- September 2014 (109)
- August 2014 (44)
- July 2014 (92)
- June 2014 (118)
- May 2014 (173)
- April 2014 (130)
- March 2014 (247)
- February 2014 (167)
- January 2014 (222)
- December 2013 (167)
- November 2013 (111)
- October 2013 (116)
- September 2013 (214)
- August 2013 (210)
- July 2013 (200)
- June 2013 (87)
- May 2013 (87)
- April 2013 (70)
- March 2013 (114)
- February 2013 (89)
- January 2013 (136)
- December 2012 (96)
- November 2012 (130)
- October 2012 (147)
- September 2012 (93)
- August 2012 (93)
- July 2012 (112)
- June 2012 (71)
- May 2012 (82)
- April 2012 (80)
- March 2012 (122)
- February 2012 (114)
- January 2012 (129)
- December 2011 (60)
- November 2011 (54)
- October 2011 (29)
- September 2011 (17)
- August 2011 (30)
- July 2011 (18)
- June 2011 (19)
- May 2011 (23)
- April 2011 (23)
- March 2011 (52)
- February 2011 (69)
- January 2011 (108)
- December 2010 (82)
- November 2010 (67)
- October 2010 (68)
- September 2010 (44)
- August 2010 (101)
- July 2010 (61)
- June 2010 (28)
- May 2010 (28)
- April 2010 (26)
- March 2010 (33)
- February 2010 (21)
- January 2010 (13)
- December 2009 (4)
- November 2009 (2)
- October 2009 (14)
- September 2009 (6)
- August 2009 (19)
- July 2009 (34)
- June 2009 (11)
- May 2009 (4)
- April 2009 (6)
- March 2009 (13)
- February 2009 (32)
- January 2009 (25)
- December 2008 (1)
- October 2008 (1)
- June 2008 (1)
- November 2007 (1)